Prostatic Acid Phosphatase: Its Current Clinical Status

Heller, John E.

doi:10.1016/s0022-5347(17)44414-4

Cited by 85 publications

(28 citation statements)

References 201 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They are based on the colorimetric determination the best-characterized reverse micelles (13 -15). of phosphate or phenol/alcohol, products released in the Human prostatic acid phosphatase (PAP) catalyzing enzyme-catalyzed reactions (1)(2)(3).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Continuous Assay for Acid Phosphatase Using Phenyl Phosphate

Luchter-Wasylewska

1996

Analytical Biochemistry

View full text Add to dashboard Cite

mentioning

confidence: 99%

“…the hydrolysis of low and high molecular phosphoesters Phenyl phosphate has been used as the acid phosphatase substrate for about 50 years (1)(2)(3). Measurements of phenol produced through enzymatic hydrolysis are is a glycoprotein composed of two subunits (16)(17)(18)(19)(20)(21).…”

mentioning

confidence: 99%

Continuous Assay for Acid Phosphatase Using Phenyl Phosphate

Luchter-Wasylewska

1996

Analytical Biochemistry

View full text Add to dashboard Cite

“…In terms of biochemical markers, the first to be used routinely in the diagnosing (5). However, a subsequent study showed that PAP levels in prostate cancer tissue were only a fraction of those identified in patients with BPH (6). Furthermore, in a study that evaluated PAP levels in 102 patients, 84% of patients that had elevated PAP levels were subsequently found to have either extracapsular extension or metastatic disease (7).…”

Section: Diagnostic and Prognostic Markersmentioning

confidence: 99%

Prostate cancer markers: An update

et al. 2016

View full text Add to dashboard Cite

Abstract. As the most common noncutaneous malignancy in American men, prostate cancer currently accounts for 29% of all diagnosed cancers, and ranks second as the cause of cancer fatality in American men. Prostatic cancer is rarely symptomatic early in its course and therefore disease presentation often implies local extension or even metastatic disease. Thus, it is extremely critical to detect and diagnose prostate cancer in its earliest stages, often prior to the presentation of symptoms. Three of the most common techniques used to detect prostate cancer are the digital rectal exam, the transrectal ultrasound, and the use of biomarkers. This review presents an update regarding the field of prostate cancer biomarkers and comments on future biomarkers. Although there is not a lack of research in the field of prostate cancer biomarkers, the discovery of a novel biomarker that may have the advantage of being more specific and effective warrants future scientific inquiry.

show abstract

“…PAP, discovered in 1938, was the first biomarker with utility in diagnosing cancer [69]. PAP was widely used in the diagnosis, prognosis and monitoring of prostate cancer from the 1950s to the 1980s [70]. However, upon the discovery of PSA and the comparison of PSA and PAP testing, PAP fell out of favor primarily due to its considerably lower sensitivity than PSA [71].…”

Section: Vaccinesmentioning

confidence: 99%

Immunotherapeutic Strategies to Target Prognostic and Predictive Markers of Cancer

2013

View full text Add to dashboard Cite

Throughout the last century medical advances in cancer treatment in the fields of surgery, radiation therapy and chemotherapy have greatly impacted patients' survival rates. Nevertheless, cancer remains a significant cause of mortality, with an estimated 7.6 million deaths worldwide in 2008, reflecting the inability of existing therapies to effectively cure disease. The emergence of vaccines and their successes in preventing the spread of infectious diseases has demonstrated the unique specificity and therapeutic potential of the immune system. This potential has driven the development of novel cancer immunotherapeutics. This review focuses on the current status of the use of immunologic effectors to target known biomarkers in cancer.

show abstract

Prostatic Acid Phosphatase: Its Current Clinical Status

Cited by 85 publications

References 201 publications

Continuous Assay for Acid Phosphatase Using Phenyl Phosphate

Continuous Assay for Acid Phosphatase Using Phenyl Phosphate

Prostate cancer markers: An update

Immunotherapeutic Strategies to Target Prognostic and Predictive Markers of Cancer

Contact Info

Product

Resources

About